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Background  and  purpose:  Cardiac  resynchronization  therapy  (CRT)  is  a  beneﬁcial  strategy
to improve  severe  cardiac  dysfunction  in  patients  with  congestive  heart  failure  (CHF).  The
improvement  of  endothelial  function  in  CHF  patients  treated  with  CRT  is  reﬂected  in  the  mor-
tality risk  reduction.  However  the  precise  mechanisms  of  the  relationship  between  CRT  and
vascular  endothelial  function  have  not  been  well  discussed.
Methods  and  subjects:  Twenty-two  severe  consecutive  CHF  patients  associated  with  dilated
cardiomyopathy  [New  York  Heart  Association  (NYHA)  class  3.3  ±  0.5,  left  ventricular  ejection
fraction (LVEF)  24.4  ±  5.9%]  were  included  in  this  study.  We  evaluated  endothelial  function,
measured by  reactive  hyperemia  peripheral  arterial  tonometry  (RH-PAT),  between  optimal  med-
ical therapy  alone  group  (medical  therapy  group:  n  =  10)  and  CRT  group  (n  =  12)  at  the  study
enrolment  and  12  weeks  later.  Furthermore  we  analyzed  the  association  between  the  RH-PAT
and cardiac  function.
Essential  results:  Both  therapies  signiﬁcantly  and  equally  improved  NYHA  class,  LVEF,  end-
diastolic left  ventricular  dimension  and  plasma  levels  of  brain  natriuretic  peptide  (BNP).  CRT
signiﬁcantly  increased  RH-PAT  index  (medical  therapy  group:  1.5  ±  0.2  to  1.5  ±  0.3,  p  =  0.824;
CRT group:  1.4  ±  0.2  to  1.7  ±  0.4,  p  =  0.003)  and  cardiac  output  (medical  therapy  group:
3.3 ±  1.1  to  3.5  ±  1.0,  p  =  0.600;  CRT  group:  2.7  ±  0.6  to  4.3  ±  1.5,  p  =  0.001),  compared  to  the
medical therapy  group.  There  was  signiﬁcant  positive  correlation  between  the  change  in  RH-PAT
index and  cardiac  output  (r  =  0.600,  p  =  0.003).
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Conclusions:  CRT  signiﬁcantly  improved  endothelial  function  through  the  improvement  of  cardiac
ared  to  optimal  medical  therapy.

















































































mass  index,  risk  factors  associated  with  the  endothelial
dysfunction  and  medical  therapy  between  the  two  groups
(Table  1).  The  baseline  blood  pressure,  NYHA  class,  plasmaoutput in  CHF  patients,  comp
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mpaired  vascular  endothelial  function  has  been  shown  to
e  associated  with  an  increase  in  mortality  risk  in  patients
ith  congestive  heart  failure  (CHF)  [1,2], since  endothelial
unction  was  thought  to  play  a  key  role  in  coordinating  tis-
ue  perfusion  and  modulating  arterial  compliance.  Cardiac
esynchronization  therapy  (CRT)  has  emerged  as  an  effective
reatment  for  congestive  heart  failure  in  the  era  of  optimal
edical  treatment  [3—5]. CRT  in  patients  with  heart  fail-
re  improves  endothelial  function,  and  this  improvement  is
eﬂected  in  the  mortality  risk  reduction  [2,6].
Endothelial  function  in  peripheral  arteries  is  currently
ssessed  by  forearm  ﬂow  mediated  vasodilation  [7,8]. How-
ver  the  results  of  forearm  ﬂow  mediated  vasodilation
ould  vary  due  to  technical  problems  encountered  during
easurement.  Thus,  forearm  ﬂow  mediated  vasodilation  is
ot  standardized  among  institutions  [9,10]. Recent  stud-
es  reported  that  the  measurement  of  digital  hyperemic
esponse  by  reactive  hyperemia  peripheral  arterial  tonom-
try  (RH-PAT)  is  a  noninvasive,  automatic  and  beneﬁcial
bjective  clinical  test  for  evaluating  endothelial  function
11,12].  In  the  present  study,  we  examined  endothelial  func-
ion  using  RH-PAT  in  CHF  patients  associated  with  dilated
ardiomyopathy  to  evaluate  the  difference  in  the  improve-
ent  of  endothelial  dysfunction  between  patients  treated
ith  medical  therapy  alone  and  medical  treatment.
ethods
wenty-two  consecutive  patients  with  left  ventricular  dys-
unction  who  were  admitted  with  CHF  associated  with
ilated  cardiomyopathy  were  included  in  this  study.  The
edical  therapy  group  consisted  of  10  patients  who  were
reated  with  optimal  medical  therapy.  The  CRT  group  con-
isted  of  12  patients  who  were  treated  with  both  optimal
edical  therapy  and  CRT.  The  inclusion  criteria  were:  New
ork  Heart  Association  (NYHA)  class  III  or  IV,  left  ventricular
jection  fraction  (LVEF)  <40%  at  admission.  Written  informed
onsent  was  obtained  from  each  patient.  The  protocol  was
pproved  by  the  hospital  human  research  committee.
eactive  hyperemia  peripheral  arterial  tonometry
igital  pulse  amplitude  was  measured  in  the  fasting  state
ith  a  peripheral  arterial  tonometry  (PAT)  device  placed  on
he  tip  of  each  index  ﬁnger  (Endo-PAT2000;  Itamar  Medical,
aesarea,  Israel).  The  principle  of  PAT  has  been  described
reviously  [13]. Brieﬂy,  a  blood  pressure  cuff  was  placed
n  one  upper  arm  (study  arm),  while  the  contralateral  arm
erved  as  a  control  (control  arm).  Peripheral  arterial  tonom-
try  probes  were  placed  on  one  ﬁnger  of  each  hand  for
l
p
sontinuous  recording  of  the  PAT  signal.  After  a 5  min  equi-
ibration  period,  the  cuff  was  inﬂated  to  60  mm  Hg  above
ystolic  pressure  or  200  mm  Hg  for  5  min,  and  then  deﬂated
o  induce  reactive  hyperemia,  whereas  PAT  recording  was
ontinued  for  10  min.
RH-PAT  data  were  automatically  analyzed  on-line  in  an
perator-independent  manner  (Endo-PAT2000  software  Ver:
.0.4).  Reactive  hyperemia  was  represented  by  the  RH-PAT
ndex,  which  was  calculated  as  the  ratio  of  the  average
mplitude  of  PAT  signal  over  1  min  starting  1.5  min  after  cuff
eﬂation  (control  arm:  A;  occluded  arm:  C)  divided  by  the
verage  amplitude  of  the  PAT  signal  for  2.5  min  before  cuff
nﬂation  (baseline)  (control  arm:  B;  occluded  arm:  D).  The
H-PAT  index  values  computed  for  the  test  arm  were  normal-
zed  to  the  control  arm  to  compensate  for  potential  systemic
hanges:
H-PAT  index = (C/D)
(A/B)
tatistical  analysis
azard  ratios,  95%  conﬁdence  intervals  (95%  CI),  and  levels
f  statistical  signiﬁcance  (p-value)  were  calculated.  Values
re  expressed  as  the  mean  ±  standard  deviation  (SD).  A  value
f  p  <  0.05  was  considered  signiﬁcant.  All  statistical  analy-
es  were  carried  out  using  SPSS,  version  11.0J  (SPSS  Inc.,
hicago,  IL,  USA).
To  compare  the  baseline  characteristics  of  the  two
roups,  data  were  analyzed  by  Student’s  t-test  for  unpaired
ata  and  2-test  (or  Fisher’s  exact  test  for  n  <  5)  for  cat-
gorical  data.  A  paired  Student’s  t-test  was  performed  to
nalyze  the  effect  of  12  weeks  of  treatment.  The  rela-
ionship  between  RH-PAT  index  and  cardiac  parameters  was
ssessed  using  Pearson’s  correlation  coefﬁcient.
esults
aseline  characteristics
mong  the  22  CHF  patients  (age,  65  ±  10  years,  64%  males,
VEF  24.4  ±  5.9%,  NYHA  class  3.3  ±  0.5)  included  in  this
tudy,  there  was  no  signiﬁcant  difference  in  sex,  age,  bodyevels  of  brain  natriuretic  peptide  (BNP),  cardiac  echo
arameters  and  RH-PAT  index  in  the  two  groups  were  not
igniﬁcantly  different  (Table  2).
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Table  1  Patient  characteristics.
Medical  therapy  group  (n  =  10) CRT  group  (n  =  12)  p-Value
Age  (years)  64.8  ±  9.6  66.2  ±  11.0  0.595
Male (n)  7  (70.0%)  6  (50.0%)  0.590
Body height  (cm)  160  ±  10  158  ±  10  0.669
BMI (kg/m2)  23.4  ±  3.4  22.1  ±  2.9  0.350
Risk factor
Hypertension 4  (40%) 4  (33%) 1.000
Diabetes mellitus 3  (30%) 2  (17%) 0.624
Dyslipidemia 4  (40%) 5  (42%) 0.691
CKD 5  (50%)  4  (33%)  0.666
Smoking 5  (50%)  5  (42%)  0.696
Medical therapy
ACE-I/ARB 9  (90%)  12  (100%)  0.455
Beta-blocker  10  (100%)  12  (100%)  1.000
CCB 1  (10%)  3  (25%)  0.594
Digitalis 1  (10%)  0  (0%)  0.455
Diuretics 9  (90%)  11  (92%)  1.000













aACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin
CKD, chronic kidney disease; CRT, cardiac resynchronization thera
Comparison  of  cardiac  echo  parameters
The  change  in  cardiac  evaluations  between  the  two  groups
is  shown  in  Table  2.  Both  therapies  signiﬁcantly  and  equally
improved  NYHA  class,  plasma  BNP  levels,  LVEF,  and  end-
diastolic  left  ventricular  dimension  (LVDd).  CRT  signiﬁcantly
increased  cardiac  output  (CO)  but  not  in  the  medical  therapy
group  (Table  2).  The  increment  of  CO  in  the  CRT  group  was
signiﬁcantly  higher  than  that  in  the  medical  therapy  group
(CRT  group;  +1.6  ±  1.3  L/min  vs.  medical  therapy  group;
+0.2  ±  1.3  L/min,  p  =  0.019).
Correlation  between  endothelial  function  and
cardiac parameters
CRT  signiﬁcantly  increased  the  RH-PAT  index  but  not  medi-





Table  2  Cardiac  parameters  and  endothelial  function.
Medical  therapy  group  (n  =  10)  CRT
Baseline  12  weeks  Base
SBP  (mm  Hg)  106  ±  25  107  ±  21  112
DBP (mm  Hg)  66  ±  15  66  ±  11  72
NYHA 3.4  ±  0.5  1.3  ±  0.5† 3.3
BNP  (pg/mL)  943  ±  551  445  ±  467† 570
LVEF  (%)  25.7  ±  6.9  35.1  ±  12.1† 23.2
LVDd  (mm)  62.5  ±  8.1  59.1  ±  10.5* 65.7
CO  (L/min)  3.3  ±  1.1  3.5  ±  1.0  2.7
RH-PAT  1.5  ±  0.2  1.5  ±  0.3  1.4
BNP, brain natriuretic polypeptide; CO, cardiac output; CRT, cardiac re
ventricular ejection fraction; LVDd, left ventricular diastolic dimension
peripheral arterial tonometry; SBP, systolic blood pressure.
* p < 0.05.
† p < 0.01, compared with the respective baseline value.eptor blocker; BMI, body mass index; CCB, Ca-channel blocker;
n  the  CRT  group  was  signiﬁcantly  higher  than  that  in  the
edical  therapy  group  (CRT  group;  +0.4  ±  0.3  vs.  medical
herapy  group;  0.0  ±  0.3,  p  =  0.007).  The  change  in  the  RH-
AT  index  signiﬁcantly  and  positively  correlated  with  the
hange  in  CO  (r  =  0.600,  p  =  0.003),  but  not  with  the  change
n  blood  pressure,  NYHA  class,  BNP  levels,  LVEF,  and  LVDd.
iscussion
he  improvement  in  endothelial  function  was  observed  only
n  the  CRT  group  although  plasma  BNP  levels,  LVEF,  LVDd,  and
YHA  class  were  similarly  ameliorated  in  both  medical  ther-
py  and  CRT  groups.  In  the  present  study,  for  the  ﬁrst  time,
e  found  that  CRT  has  a  great  advantage  for  the  improve-
ent  in  endothelial  dysfunction  through  the  improvement
n  CO  compared  to  medical  therapy  alone  in  patients  with
HF  associated  with  dilated  cardiomyopathy.
 group  (n  =  12)  All  (n  =  22)
line  12  weeks  Baseline  12  weeks
 ±  18  110  ±  13  109  ±  21  109  ±  17
 ±  12  68  ±  10  69  ±  13  67  ±  10
 ±  0.5  1.3  ±  0.5† 3.3  ±  0.5  1.3  ±  0.5†
 ±  494  310  ±  247* 739  ±  542  371  ±  361†
 ±  5.0  37.5  ±  14.0† 24.4  ±  5.9  36.4  ±  12.9†
 ±  5.6  59.4  ±  9.8* 64.2  ±  6.9  59.3  ±  9.9†
 ±  0.6  4.3  ±  1.5† 3.0  ±  0.9  4.0  ±  1.3†
 ±  0.2  1.7  ±  0.4† 1.4  ±  0.2  1.6  ±  0.4*
synchronization therapy; DBP, diastolic blood pressure; LVEF, left























































A  previous  randomized  trial  (MIRACLE)  demonstrated  that
RT  showed  a  signiﬁcant  improvement  in  the  heart  failure
linical  status  compared  to  medical  therapy  alone  [4].  Also
RT  decreased  the  risk  of  heart  failure  events  in  relatively
symptomatic  patients  with  a  low  ejection  fraction  [5].  Katz
t  al.  have  reported  that  endothelial  dysfunction  in  CHF  is
ssociated  with  an  increased  mortality  risk  in  subjects  with
ither  ischemic  or  non-ischemic  CHF  [1].  CRT  for  patients
ith  heart  failure  improves  endothelial  function  [6]  and  this
s  reﬂected  in  the  mortality  risk  reduction  [2].  However,  the
echanism  of  improvement  of  endothelial  dysfunction  by
RT  has  not  been  clariﬁed.  Our  study  might  explain  one  of
ts  mechanisms.
Regarding  the  improvement  effect  of  endothelial  dys-
unction  in  CHF  patients,  several  mechanisms  have  been
roposed.  Decreased  nitric  oxide  production  associated  with
ndothelial  nitric  oxide  synthase  expression  and  increased
itric  oxide  degradation  by  oxidative  stress  have  been
roposed  as  the  mechanisms  of  endothelial  dysfunction
14—17].  A  decrease  in  CO  decreases  shear  stress,  thereby
ecreasing  the  vascular  nitric  oxide  bioavailability  [18]. In
he  present  study,  the  CO  evaluated  by  echocardiography
igniﬁcantly  increased  in  the  CRT  group,  but  not  in  the
roup  on  medical  therapy  alone.  Indeed,  there  was  a  sig-
iﬁcant  positive  correlation  between  the  RH-PAT  and  CO.
hese  improvements  in  CO  might  increase  nitric  oxide  pro-
uction  through  an  increase  in  shear  stress  and  thus  result
n  improved  endothelial  function.
It  is  already  known  that  many  conventional  medications
uch  as  angiotensin-converting  enzyme  inhibitors  ameliorate
ascular  endothelial  dysfunction.  However,  several  stud-
es  have  reported  that  optimal  medical  therapy  including
ngiotensin-converting  enzyme  inhibitors  did  not  improve
ndothelial  dysfunction  in  heart  failure  patients  [19,20].
hese  ﬁndings  explain  the  absence  of  improvement  in
ndothelial  function  in  the  medical  therapy  group  in  the
resent  study.
onclusion
ardiac  resynchronization  therapy  prominently  improves
ndothelial  function  through  the  improvement  in  CO  in
atients  with  severe  CHF  associated  with  dilated  cardiomy-
pathy.  It  could  be  an  effective  clinical  strategy  to  reduce




his  study  was  partly  presented  at  the  81st  Scientiﬁc  Ses-
ions  of  the  American  Heart  Association,  New  Orleans,  LA,
SA,  November  8—12,  2008.eferences
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